PTC Therapeutics upgraded by BofA Securities with a new price target

3/11/25 7:43:05 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

BofA Securities upgraded PTC Therapeutics from Underperform to Neutral and set a new price target of $55.00 from $41.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PTCT

Date	Price Target	Rating	Analyst
6/17/2025	$80.00	Buy	Truist
5/9/2025	$68.00	Neutral → Buy	BofA Securities
5/7/2025	$40.00	Sell → Neutral	Citigroup
3/11/2025	$41.00 → $55.00	Underperform → Neutral	BofA Securities
3/7/2025	$55.00	Sector Perform	Scotiabank
12/13/2024	$45.00 → $67.00	Equal-Weight → Overweight	Morgan Stanley
12/3/2024	$39.00 → $63.00	Sector Perform → Outperform	RBC Capital Mkts
10/10/2024		Mkt Perform	Raymond James